Geron Corporation and CXR Biosciences Conclude Collaboration to Develop In Vitro Assays Using hESC-Derived Hepatocytes

MENLO PARK, Calif. & DUNDEE, Scotland--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) and CXR Biosciences Ltd. today announced the conclusion of a research collaboration that focused on the development of human embryonic stem cell (hESC)-derived hepatocytes for use in in vitro assays of drug metabolism and toxicity.

Back to news